Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Management of Peripheral Neuropathy Induced by Chemotherapy

Author(s): Maayan Fradkin, Ron Batash, Shiran Elmaleh*, Ronen Debi , Pamela Schaffer , Moshe Schaffer and Noam Asna

Volume 26, Issue 25, 2019

Page: [4698 - 4708] Pages: 11

DOI: 10.2174/0929867326666190107163756

Price: $65

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is considered a severe side effect of therapeutic agents with limited treatment options. The incidence of CIPN in cancer patients is approximately 3–7% in cytostatic monotherapy and as high as 38% in cases of polychemotherapy. The prevalence of CIPN was found to be 68% within the first month of chemotherapy treatment. In some cases, CIPN can resolve, partially or completely, after completion of the treatment; in other cases, it can remain for a long time and affect the patient's quality of life.

Objective: The aim of this study is to present up-to-date data regarding available treatment options for the management of CIPN.

Materials and Methods: The up-to-date guidelines of ESMO (European Society for Medical Oncology), ASCO (American Society of Clinical Oncology), ONS (Oncology Nursing Society), NCI (National Cancer Institute), and NCCN (National Comprehensive Cancer Network) were reviewed and included in the manuscript.

Results: The use of tricyclic antidepressant (TCA), selective serotonin norepinephrine reuptake inhibitor (SSNRI), pregabalin, and gabapentin are recommended as first-line treatment. Other treatment options were offered as second and third lines of treatment (lidocaine patches, capsaicin high-concentration patches, tramadol, and strong opioids, respectively); however, lower significance was demonstrated. Inconclusive results were found in the use of cannabinoids, drug combinations, antiepileptics, antidepressants, and topical drugs.

Conclusion: TCA, other antidepressants, and opioids could be recommended as treatment. Yet, we could not recommend an ideal therapeutic agent for the prevention or treatment of CIPN. Therefore, CIPN continues to be a challenge to clinicians and our patients.

Keywords: CIPN, neuropathy, chemotherapy, cannabis, opioid, TCA, SSNR1.

« Previous Next »
[1]
Jensen, T.S.; Baron, R.; Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.C.; Treede, R.D. A new definition of neuropathic pain. Pain, 2011, 152(10), 2204-2205.
[http://dx.doi.org/10.1016/j.pain.2011.06.017] [PMID: 21764514]
[2]
Umapathi, T.; Chaudhry, V. Toxic neuropathy. Curr. Opin. Neurol., 2005, 18(5), 574-580.
[http://dx.doi.org/10.1097/01.wco.0000180158.34713.aa] [PMID: 16155443]
[3]
Addington, J.; Freimer, M. Chemotherapy-induced periph- eral neuropathy: an update on the current understanding. F1000 Res., 2016, 5, 1466.
[4]
Kanbayashi, Y.; Hosokawa, T. Peripheral neuropathies especially in cancer patients: focus on chemotherapy- induced peripheral neuropathies and post-herpetic neuralgia. Int. J. Cancer Res. Prev., 2015, 8(4), 8566.
[5]
Grisold, W.; Cavaletti, G.; Windebank, A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol., 2012, 14(Suppl. 4), iv45-iv54.
[http://dx.doi.org/10.1093/neuonc/nos203] [PMID: 23095830]
[6]
Massey, R.L.; Kim, H.K.; Abdi, S. Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions. Can. J. Anaesth., 2014, 61(8), 754-762.
[http://dx.doi.org/10.1007/s12630-014-0171-4] [PMID: 24804574]
[7]
Renn, C.L.; Carozzi, V.A.; Rhee, P.; Gallop, D.; Dorsey, S.G.; Cavaletti, G. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol. Pain, 2011, 7, 29.
[http://dx.doi.org/10.1186/1744-8069-7-29] [PMID: 21521528]
[8]
Sisignano, M.; Baron, R.; Scholich, K.; Geisslinger, G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat. Rev. Neurol., 2014, 10(12), 694-707.
[http://dx.doi.org/10.1038/nrneurol.2014.211] [PMID: 25366108]
[9]
Flatters, S.J.L.; Dougherty, P.M.; Colvin, L.A. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br. J. Anaesth., 2017, 119(4), 737-749.
[http://dx.doi.org/10.1093/bja/aex229] [PMID: 29121279]
[10]
Rostock, M.; Jaroslawski, K.; Guethlin, C.; Ludtke, R.; Schröder, S.; Bartsch, H.H. Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid. Based Complement. Alternat. Med., 2013, 2013349653
[http://dx.doi.org/10.1155/2013/349653] [PMID: 24066010]
[11]
Pachman, D.R.; Watson, J.C.; Lustberg, M.B.; Wagner-Johnston, N.D.; Chan, A.; Broadfield, L.; Cheung, Y.T.; Steer, C.; Storey, D.J.; Chandwani, K.D.; Paice, J.; Jean-Pierre, P.; Oh, J.; Kamath, J.; Fallon, M.; Strik, H.; Koeppen, S.; Loprinzi, C.L. Management options for established chemotherapy-induced peripheral neuropathy. Support. Care Cancer, 2014, 22(8), 2281-2295.
[http://dx.doi.org/10.1007/s00520-014-2289-x] [PMID: 24879391]
[12]
Wolf, S.L.; Barton, D.L.; Qin, R.; Wos, E.J.; Sloan, J.A.; Liu, H.; Aaronson, N.K.; Satele, D.V.; Mattar, B.I.; Green, N.B.; Loprinzi, C.L. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support. Care Cancer, 2012, 20(3), 625-632.
[http://dx.doi.org/10.1007/s00520-011-1141-9] [PMID: 21479990]
[13]
Gewandter, J.S.; Fan, L.; Magnuson, A.; Mustian, K. Pep- pone, L.; Heckler, C.; Hopkins, J.; Tejani, M.; Morrow, G.R.; Mohile, S.G. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study. Support. Care Cancer, 2013, 21(7), 2059-2066.
[http://dx.doi.org/10.1007/s00520-013-1766-y] [PMID: 23446880]
[14]
Loprinzi, C.L.; Reeves, B.N.; Dakhil, S.R.; Sloan, J.A.; Wolf, S.L.; Burger, K.N.; Kamal, A.; Le-Lindqwister, N.A.; Soori, G.S.; Jaslowski, A.J.; Novotny, P.J.; Lachance, D.H. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol., 2011, 29(11), 1472-1478.
[http://dx.doi.org/10.1200/JCO.2010.33.0308] [PMID: 21383290]
[15]
Taillibert, S.; Le Rhun, E.; Chamberlain, M.C. Chemotherapy-related neurotoxicity. Curr. Neurol. Neurosci. Rep., 2016, 16(9), 81.
[http://dx.doi.org/10.1007/s11910-016-0686-x] [PMID: 27443648]
[16]
Cata, J.P.; Weng, H.R.; Lee, B.N.; Reuben, J.M.; Dougherty, P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol., 2006, 72(3), 151-169.
[PMID: 16493391]
[17]
Park, S.B.; Krishnan, A.V.; Lin, C.S.; Goldstein, D.; Friedlander, M.; Kiernan, M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem., 2008, 15(29), 3081-3094.
[http://dx.doi.org/10.2174/092986708786848569] [PMID: 19075655]
[18]
Han, Y.; Smith, M.T. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front. Pharmacol., 2013, 4, 156.
[http://dx.doi.org/10.3389/fphar.2013.00156] [PMID: 24385965]
[19]
Pignataro, R.M.; Swisher, A.K. Chemotherapy induced peripheral neuropathy: risk factors, pathophysiology, assessment, and potential physical therapy interventions. Rehabil. Oncol., 2010, 28(2), 10-18.
[http://dx.doi.org/10.1097/01893697-201028020-00002]
[20]
Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg, M.B.; Paice, J.; Schneider, B.; Smith, M.L.; Smith, T.; Terstriep, S.; Wagner-Johnston, N.; Bak, K.; Loprinzi, C.L. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol., 2014, 32(18), 1941-1967.
[http://dx.doi.org/10.1200/JCO.2013.54.0914] [PMID: 24733808]
[21]
Visovsky, C.; Collins, M.; Abbott, L.; Aschenbrenner, J.; Hart, C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs., 2007, 11(6), 901-913.
[http://dx.doi.org/10.1188/07.CJON.901-913] [PMID: 18063548]
[22]
Wolf, S.; Barton, D.; Kottschade, L.; Grothey, A.; Loprinzi, C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer, 2008, 44(11), 1507-1515.
[http://dx.doi.org/10.1016/j.ejca.2008.04.018] [PMID: 18571399]
[23]
Kajih, R.N.; Moore, C.D. Management of chemotherapy- induced peripheral neuropathy. US Pharm., 2015, 40(1), HS5-HS10.
[24]
Gamelin, L.; Boisdron-Celle, M.; Delva, R.; Guérin-Meyer, V.; Ifrah, N.; Morel, A.; Gamelin, E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res., 2004, 10(12 Pt 1), 4055-4061.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0666] [PMID: 15217938]
[25]
Durand, J.P.; Deplanque, G.; Montheil, V.; Gornet, J.M.; Scotte, F.; Mir, O.; Cessot, A.; Coriat, R.; Raymond, E.; Mitry, E.; Herait, P.; Yataghene, Y.; Goldwasser, F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol., 2012, 23(1), 200-205.
[http://dx.doi.org/10.1093/annonc/mdr045] [PMID: 21427067]
[26]
Piccolo, J.; Kolesar, J.M. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am. J. Health Syst. Pharm., 2014, 71(1), 19-25.
[http://dx.doi.org/10.2146/ajhp130126] [PMID: 24352178]
[27]
Salehi, Z.; Roayaei, M. Effect of vitamin E on oxaliplatin- induced peripheral neuropathy prevention: a randomized controlled trial. Int. J. Prev. Med., 2015, 6, 104.
[http://dx.doi.org/10.4103/2008-7802.169021] [PMID: 26682028]
[28]
Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Kamerman, P.R.; Lund, K.; Moore, A.; Raja, S.N.; Rice, A.S.; Rowbotham, M.; Sena, E.; Siddall, P.; Smith, B.H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol., 2015, 14(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710]
[29]
Smith, E.M.; Pang, H.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Fadul, C.E.; Knox, C.; Le-Lindqwister, N.; Gilman, P.B.; Shapiro, C.L. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 2013, 309(13), 1359-1367.
[http://dx.doi.org/10.1001/jama.2013.2813] [PMID: 23549581]
[30]
Kanat, O.; Ertas, H.; Caner, B. Platinum-induced neurotoxicity: a review of possible mechanisms. World J. Clin. Oncol., 2017, 8(4), 329-335.
[http://dx.doi.org/10.5306/wjco.v8.i4.329] [PMID: 28848699]
[31]
Majithia, N.; Temkin, S.M.; Ruddy, K.J.; Beutler, A.S.; Hershman, D.L.; Loprinzi, C.L. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support. Care Cancer, 2016, 24(3), 1439-1447.
[http://dx.doi.org/10.1007/s00520-015-3063-4] [PMID: 26686859]
[32]
Stubblefield, M.D.; Burstein, H.J.; Burton, A.W.; Custodio, C.M.; Deng, G.E.; Ho, M.; Junck, L.; Morris, G.S.; Paice, J.A.; Tummala, S.; Von Roenn, J.H. NCCN task force report: management of neuropathy in cancer. J. Natl. Compr. Canc. Netw., 2009, 7(Suppl. 5), S1-S26.
[http://dx.doi.org/10.6004/jnccn.2009.0078] [PMID: 19755042]
[33]
Kong, V.K.; Irwin, M.G. Adjuvant analgesics in neuropathic pain. Eur. J. Anaesthesiol., 2009, 26(2), 96-100.
[http://dx.doi.org/10.1097/EJA.0b013e328318c706] [PMID: 19142081]
[34]
Portenoy, R.K. Adjuvant analgesics in pain management. In: Textbook of Palliative Medicine; B.R. Ferrell and Nessa Coyle, Eds; Oxford University Press, Oxford. , 2010; p. 361.
[35]
Dworkin, R.H.; O’Connor, A.B.; Audette, J.; Baron, R.; Gourlay, G.K.; Haanpää, M.L.; Kent, J.L.; Krane, E.J. Le- Bel, A.A.; Levy, R.M.; Mackey, S.C.; Mayer, J.; Miask- owski, C.; Raja, S.N.; Rice, A.S.C.; Schmader, K.E.; Stacey, B.; Stanos, S.; Treede, R.D.; Turk, D.C.; Walco, G.A.; Wells, C.D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc., 2010, 85(3)(Suppl.), S3-S14.
[http://dx.doi.org/10.4065/mcp.2009.0649] [PMID: 20194146]
[36]
Fornasari, D. Pharmacotherapy for neuropathic pain: a review. Pain Ther., 2017, 6(S1)(Suppl. 1), 25-33.
[http://dx.doi.org/10.1007/s40122-017-0091-4] [PMID: 29178034]
[37]
Atreya, S. Pregabalin in chemotherapy induced neuropathic pain. Indian J. Palliat. Care, 2016, 22(1), 101-103.
[http://dx.doi.org/10.4103/0973-1075.173941] [PMID: 26962289]
[38]
Xiao, W.; Boroujerdi, A.; Bennett, G.J.; Luo, Z.D. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience, 2007, 144(2), 714-720.
[http://dx.doi.org/10.1016/j.neuroscience.2006.09.044] [PMID: 17084535]
[39]
Rao, R.D.; Michalak, J.C.; Sloan, J.A.; Loprinzi, C.L.; Soori, G.S.; Nikcevich, D.A.; Warner, D.O.; Novotny, P.; Kutteh, L.A.; Wong, G.Y. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, 2007, 110(9), 2110-2118.
[http://dx.doi.org/10.1002/cncr.23008] [PMID: 17853395]
[40]
Hausheer, F.H.; Schilsky, R.L.; Bain, S.; Berghorn, E.J.; Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin. Oncol., 2006, 33(1), 15-49.
[http://dx.doi.org/10.1053/j.seminoncol.2005.12.010] [PMID: 16473643]
[41]
Saarto, T.; Wiffen, P.J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev., 2005, (3)CD005454
[PMID: 16034979]
[42]
Gewandter, J.S.; Mohile, S.G.; Heckler, C.E.; Ryan, J.L.; Kirshner, J.J.; Flynn, P.J.; Hopkins, J.O.; Morrow, G.R. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support. Care Cancer, 2014, 22(7), 1807-1814.
[http://dx.doi.org/10.1007/s00520-014-2158-7] [PMID: 24531792]
[43]
Ocean, A.J.; Vahdat, L.T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support. Care Cancer, 2004, 12(9), 619-625.
[http://dx.doi.org/10.1007/s00520-004-0657-7] [PMID: 15258838]
[44]
Aziz, M.T.; Good, B.L.; Lowe, D.K. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann. Pharmacother., 2014, 48(5), 626-632.
[http://dx.doi.org/10.1177/1060028014525033] [PMID: 24577146]
[45]
Yang, Y.H.; Lin, J.K.; Chen, W.S.; Lin, T.C.; Yang, S.H.; Jiang, J.K.; Chang, S.C.; Lan, Y.T.; Lin, C.C.; Yen, C.C.; Tzeng, C.H.; Wang, W.S.; Chiang, H.L.; Teng, C.J.; Teng, H.W. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support. Care Cancer, 2012, 20(7), 1491-1497.
[http://dx.doi.org/10.1007/s00520-011-1237-2] [PMID: 21814779]
[46]
Otake, A.; Yoshino, K.; Ueda, Y.; Sawada, K.; Mabuchi, S.; Kimura, T.; Kobayashi, E.; Isobe, A.; Egawa-Takata, T.; Matsuzaki, S.; Fujita, M.; Kimura, T. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res., 2015, 35(1), 359-363.
[PMID: 25550572]
[47]
Fallon, M.T.; Storey, D.J.; Krishan, A.; Weir, C.J.; Mitchell, R.; Fleetwood-Walker, S.M.; Scott, A.C.; Colvin, L.A. Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support. Care Cancer, 2015, 23(9), 2769-2777.
[http://dx.doi.org/10.1007/s00520-015-2642-8] [PMID: 25680765]
[48]
Üçeyler, N.; Sommer, C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain Ther., 2014, 3(2), 73-84.
[http://dx.doi.org/10.1007/s40122-014-0027-1] [PMID: 25069571]
[49]
Barton, D.L.; Wos, E.J.; Qin, R.; Mattar, B.I.; Green, N.B.; Lanier, K.S.; Bearden, J.D., III; Kugler, J.W.; Hoff, K.L.; Reddy, P.S.; Rowland, K.M., Jr; Riepl, M.; Christensen, B.; Loprinzi, C.L. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support. Care Cancer, 2011, 19(6), 833-841.
[http://dx.doi.org/10.1007/s00520-010-0911-0] [PMID: 20496177]
[50]
Attal, N.; Cruccu, G.; Baron, R.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Nurmikko, T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol., 2010, 17(9), 1113-e88.
[http://dx.doi.org/10.1111/j.1468-1331.2010.02999.x] [PMID: 20402746]
[51]
Liu, Y.C.; Wang, W.S. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer, 2012, 118(6), 1718-1725.
[http://dx.doi.org/10.1002/cncr.26430] [PMID: 21837673]
[52]
Bennett, M.I. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat. Med., 2011, 25(5), 553-559.
[http://dx.doi.org/10.1177/0269216310378546] [PMID: 20671006]
[53]
Wiffen, P.J.; Derry, S.; Bell, R.F.; Rice, A.S.; Tölle, T.R.; Phillips, T.; Moore, R.A. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2017, 6CD007938
[http://dx.doi.org/10.1002/14651858.CD007938.pub4] [PMID: 28597471]
[54]
Nagashima, M.; Ooshiro, M.; Moriyama, A.; Sugishita, Y.; Kadoya, K.; Sato, A.; Kitahara, T.; Takagi, R.; Urita, T.; Yoshida, Y.; Tanaka, H.; Oshiro, T.; Okazumi, S.; Katoh, R. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support. Care Cancer, 2014, 22(6), 1579-1584.
[http://dx.doi.org/10.1007/s00520-014-2132-4] [PMID: 24452412]
[55]
Brzeziński, K. Chemotherapy-induced peripheral neuropathy. Part II. Prevention. Contemp. Oncol. (Pozn.), 2012, 16(3), 258-261.
[http://dx.doi.org/10.5114/wo.2012.29296] [PMID: 23788891]
[56]
Moore, R.J.; Groninger, H. Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Cureus, 2013, 5(6)e124
[PMID: 25144779]
[57]
Nishikawa, T.; Hasegawa, K.; Shintani, D.; Yano, Y.; Sato, S.; Yabuno, A.; Kurosaki, A.; Yoshida, H.; Fujiwara, K. Combination therapy of pregabalin with tramadol for treat- ment of peripheral neuropathy in patients with gynecological cancer receiving taxane containing chemotherapy. Gan To Kagaku Ryoho, 2017, 44(3), 227-231.
[PMID: 28292992]
[58]
Schröder, S.; Beckmann, K.; Franconi, G.; Meyer-Hamme, G.; Friedemann, T.; Greten, H.J.; Rostock, M.; Efferth, T. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evid. Based Complement. Alternat. Med., 2013.2013423713
[http://dx.doi.org/10.1155/2013/423713] [PMID: 23983777]
[59]
Wilsey, B.; Marcotte, T.; Deutsch, R.; Gouaux, B.; Sakai, S.; Donaghe, H. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain, 2013, 14(2), 136-148.
[http://dx.doi.org/10.1016/j.jpain.2012.10.009] [PMID: 23237736]
[60]
Wilsey, B.; Marcotte, T.D.; Deutsch, R.; Zhao, H.; Prasad, H.; Phan, A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J. Pain, 2016, 17(9), 982-1000.
[http://dx.doi.org/10.1016/j.jpain.2016.05.010] [PMID: 27286745]
[61]
Swift, W.; Gates, P.; Dillon, P. Survey of Australians using cannabis for medical purposes. Harm Reduct. J., 2005, 2, 18.
[http://dx.doi.org/10.1186/1477-7517-2-18] [PMID: 16202145]
[62]
King, K.M.; Myers, A.M.; Soroka-Monzo, A.J.; Tuma, R.F.; Tallarida, R.J.; Walker, E.A.; Ward, S.J. Single and combined effects of Δ9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br. J. Pharmacol., 2017, 174(17), 2832-2841.
[http://dx.doi.org/10.1111/bph.13887] [PMID: 28548225]
[63]
Thompson, D.F.; Brooks, K.G. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J. Clin. Pharm. Ther., 2015, 40(5), 496-503.
[http://dx.doi.org/10.1111/jcpt.12297] [PMID: 26059975]
[64]
Tsavaris, N.; Kopterides, P.; Kosmas, C.; Efthymiou, A.; Skopelitis, H.; Dimitrakopoulos, A.; Pagouni, E.; Pikazis, D.; Zis, P.V.; Koufos, C. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med., 2008, 9(8), 1209-1216.
[http://dx.doi.org/10.1111/j.1526-4637.2007.00325.x] [PMID: 19067834]
[65]
Verma, V.; Singh, N.; Singh Jaggi, A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr. Neuropharmacol., 2014, 12(1), 44-56.
[http://dx.doi.org/10.2174/1570159X1201140117162802] [PMID: 24533015]
[66]
Derry, S.; Moore, R.A. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2012, (9)CD010111
[http://dx.doi.org/10.1002/14651858.CD010111] [PMID: 22972149]
[67]
Duehmke, R.M.; Derry, S.; Wiffen, P.J.; Bell, R.F.; Aldington, D.; Moore, R.A. Tramadol for neuropathic pain in adults. Cochrane Database Syst. Rev., , 2017, 6CD003726.
[PMID: 28616956]
[68]
Visovsky, C.; Collins, M.; Abbott, L.; Aschenbrenner, J.; Hart, C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs., 2007, 11(6), 901-913.
[http://dx.doi.org/10.1188/07.CJON.901-913] [PMID: 18063548]
[69]
Tofthagen, C.; Visovsky, C.M.; Hopgood, R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin. J. Oncol. Nurs., 2013, 17(2), 138-144.
[http://dx.doi.org/10.1188/13.CJON.138-144] [PMID: 23538249]
[70]
Andrade, D.C.D.; Teixeira, M.J.; Galhardoni, R.; Ferreira, K.A.S.L.; Malieno, P.B.; Scisci, N.; Riechelmann, R.P.; Teixeira, W.G.J.; Saragiotto, D.F.; Silva, V.A.; Raicher, I.; Castro, I.D.; Parravano, D.; Fukushima, J.T.; Lefaucheur, J.P.; Bouhassira, D. Macarenco. R.Se.S.; Mello, E.S.D.; Hoff, P.M. A phase III, randomized, double-blind, placebo- controlled trial to evaluate the efficacy and safety of pre- gabalin in the prevention and reduction of oxaliplatin- induced painful neuropathy (PreOx). J. Clin. Oncol., 2015, 33(15)(Suppl.), 3575-3575.
[71]
Desideri, I.; Francolini, G.; Becherini, C.; Terziani, F. Delli- Paoli C.; Olmetto E.; Loi M.; Perna M.; Meattini I.; Scotti V.; Greto D.; Bonomo P.; Sulprizio S.; Livi L. Use of an alpha lipoic, methylsulfonylmethane and bromelaindietary suplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospectivestudy. Med. Oncol., 2017, 34(3), 46.
[http://dx.doi.org/10.1007/s12032-017-0907-4] [PMID: 28205185]
[72]
Ripamonti, C.I.; Santini, D.; Maranzano, E.; Berti, M.; Roila, F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann. Oncol., 2012, 23(Suppl. 7), vii139-vii 154..
[http://dx.doi.org/10.1093/annonc/mds233] [PMID: 22997447]
[73]
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. NCI, NIH, DHHS. November 27 2017.
[74]
World Alliance for Patient Safety. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems., Geneva:World Health Organization.(WHO/EIP/SPO/QPS/05.3). . 2005.
[75]
International Organization for Standardization. 1988 ISO Standards Handbook 1, 3rd Edition. Documentation and information. Switzerland: ISO in World Health Organication Family of International Classifications, June. , 2004.
[76]
Katzung, B.G.; Masters, S.B.; Trevor, A.J. Basic and clinical pharmacology, 12th ed; , 2012.
[77]
Blackwell, B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs, 1981, 21(3), 201-219.
[http://dx.doi.org/10.2165/00003495-198121030-00002] [PMID: 6114849]

Rights & Permissions Print Cite
Article Metrics
111
10
© 2024 Bentham Science Publishers | Privacy Policy